cervicalcancerdepressionherpeszosterq15ydyslipidemia< 60y.o.40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorpneumococcalstatin52y.o.40-59 y.o.,ASCVD ≥10%, lowbleeding riskraloxifeneovariancancerhypertensionTyrer-Cuzickmodel≥ 126mg/dL≥ 100mg/dLanxiety≥6.5%FractureRiskAssessmentToolHIV≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorq1ymammogramtobaccousePREVENTequationbreastcancertamoxifen75y.o.≥20%hormonetherapy50y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsq1-2ymammogrambased on lifeexpectancy /health statuslungcancer40y.o.q5y≥ 200mg/dLdiabetesTimedup andgo testHepatitisC≤q2yq3ycardiovasculardiseaseq2y≥5.7%1 dose; 2doses (2-6monthsapart) ifimmunocomp40-70 y.o.,ASCVD ≥10%, lowbleeding risk65y.o.multidoseinitial series,then 1 doseat 2-6months3%q1yaspirindementia60y.o.aromataseinhibitorsHepatitisBinsufficientevidenceforscreeningcolorectalcanceroverweight/ obesityGailmodelwomenage 55-64 y.o.≥ 140mg/dLcommunity-dwelling,postmenopausalwomen2 doses,2-6monthsapartcervicalcancerdepressionherpeszosterq15ydyslipidemia< 60y.o.40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorpneumococcalstatin52y.o.40-59 y.o.,ASCVD ≥10%, lowbleeding riskraloxifeneovariancancerhypertensionTyrer-Cuzickmodel≥ 126mg/dL≥ 100mg/dLanxiety≥6.5%FractureRiskAssessmentToolHIV≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorq1ymammogramtobaccousePREVENTequationbreastcancertamoxifen75y.o.≥20%hormonetherapy50y.o.40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsq1-2ymammogrambased on lifeexpectancy /health statuslungcancer40y.o.q5y≥ 200mg/dLdiabetesTimedup andgo testHepatitisC≤q2yq3ycardiovasculardiseaseq2y≥5.7%1 dose; 2doses (2-6monthsapart) ifimmunocomp40-70 y.o.,ASCVD ≥10%, lowbleeding risk65y.o.multidoseinitial series,then 1 doseat 2-6months3%q1yaspirindementia60y.o.aromataseinhibitorsHepatitisBinsufficientevidenceforscreeningcolorectalcanceroverweight/ obesityGailmodelwomenage 55-64 y.o.≥ 140mg/dLcommunity-dwelling,postmenopausalwomen2 doses,2-6monthsapart

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. cervical cancer
  2. depression
  3. herpes zoster
  4. q15y
  5. dyslipidemia
  6. < 60 y.o.
  7. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  8. pneumococcal
  9. statin
  10. 52 y.o.
  11. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  12. raloxifene
  13. ovarian cancer
  14. hypertension
  15. Tyrer-Cuzick model
  16. ≥ 126 mg/dL
  17. ≥ 100 mg/dL
  18. anxiety
  19. ≥ 6.5%
  20. Fracture Risk Assessment Tool
  21. HIV
  22. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  23. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  24. q1y mammogram
  25. tobacco use
  26. PREVENT equation
  27. breast cancer
  28. tamoxifen
  29. 75 y.o.
  30. ≥ 20%
  31. hormone therapy
  32. 50 y.o.
  33. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  34. q1-2y mammogram based on life expectancy / health status
  35. lung cancer
  36. 40 y.o.
  37. q5y
  38. ≥ 200 mg/dL
  39. diabetes
  40. Timed up and go test
  41. Hepatitis C
  42. ≤ q2y
  43. q3y
  44. cardiovascular disease
  45. q2y
  46. ≥ 5.7%
  47. 1 dose; 2 doses (2-6 months apart) if immunocomp
  48. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  49. 65 y.o.
  50. multidose initial series, then 1 dose at 2-6 months
  51. 3%
  52. q1y
  53. aspirin
  54. dementia
  55. 60 y.o.
  56. aromatase inhibitors
  57. Hepatitis B
  58. insufficient evidence for screening
  59. colorectal cancer
  60. overweight / obesity
  61. Gail model
  62. women age 55-64 y.o.
  63. ≥ 140 mg/dL
  64. community-dwelling, postmenopausal women
  65. 2 doses, 2-6 months apart